COVID-19 and Cancer Consortium Registry (CCC19)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04354701|
Recruitment Status : Active, not recruiting
First Posted : April 21, 2020
Last Update Posted : April 5, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|COVID-19 Invasive Malignancy (Any Type)||Other: Web-based REDCap survey|
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generating and hypothesis-supporting findings that are generalizable to the population at large. Specifically:
I. Characterize patient factors, such as pre-existing comorbidities, baseline medication exposures, cancer type, status, and treatment, and demographic factors that are associated with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive), including severity and fatality, in patients with cancer.
II. Describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation.
III. Evaluate the association of COVID-19 with cancer outcomes.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||19275 participants|
|Target Follow-Up Duration:||36 Months|
|Official Title:||The COVID-19 and Cancer Consortium (CCC19) Registry|
|Actual Study Start Date :||March 17, 2020|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2025|
- Other: Web-based REDCap survey
The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
- Web-based REDCap survey [ Time Frame: Approximately 18 months ]The survey includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
• Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria:
- Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19.
- Current or past medical history of invasive malignancy (any type)
- Participants at international sites not explicitly listed below
- Non-healthcare providers (or their proxies)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04354701
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Jeremy Warner, MD||Vanderbilt-Ingram Cancer Center|
|Responsible Party:||Jeremy Warner, Principal Investigator, Vanderbilt-Ingram Cancer Center|
|Other Study ID Numbers:||
VICC MD 2032
|First Posted:||April 21, 2020 Key Record Dates|
|Last Update Posted:||April 5, 2023|
|Last Verified:||April 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases